Aquestive Therapeutics Inc
$ 4.17
-0.95%
12 Jun - close price
- Market Cap 523,127,000 USD
- Current Price $ 4.17
- High / Low $ 4.30 / 4.17
- Stock P/E N/A
- Book Value -0.27
- EPS -0.61
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE N/A %
- 52 Week High 7.55
- 52 Week Low 2.93
About
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.
Analyst Target Price
$8.89
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-04 | 2025-11-05 | 2025-08-11 | 2025-05-12 | 2025-03-05 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-06 | 2023-08-07 |
| Reported EPS | -0.05 | -0.26 | -0.11 | -0.12 | -0.22 | -0.1607 | -0.11 | -0.01 | -0.17 | -0.09 | -0.03 | -0.1 |
| Estimated EPS | -0.13 | -0.13 | -0.11 | -0.17 | -0.16 | -0.1325 | -0.12 | -0.11 | -0.08 | -0.07 | -0.11 | -0.12 |
| Surprise | 0.08 | -0.13 | 0 | 0.05 | -0.06 | -0.0282 | 0.01 | 0.1 | -0.09 | -0.02 | 0.08 | 0.02 |
| Surprise Percentage | 61.5385% | -100% | 0% | 29.4118% | -37.5% | -21.283% | 8.3333% | 90.9091% | -112.5% | -28.5714% | 72.7273% | 16.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.12 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AQST
2026-06-12 16:09:00
Aquestive Therapeutics director Abigail L. Jenkins was granted 50,500 non-qualified stock options with an exercise price of $3.99 per share. These options will vest entirely on June 10, 2027, provided she remains continuously employed by the company. This award is a compensation grant, not a market transaction, and it represents potential future ownership for Ms. Jenkins.
2026-06-12 16:09:00
Aquestive Therapeutics (AQST) director Gregory B. Brown received a grant of 50,500 stock options with an exercise price of $3.99 per share. These options will vest 100% on June 10, 2027, contingent on his continued service to the company. Following this grant, Brown directly holds 75,085 shares of Common Stock and the newly issued 50,500 stock options.
2026-06-11 11:00:00
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aquestive Therapeutics, Inc. (AQST) regarding corporate wrongdoing. The firm encourages stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis and aims to restore investor capital and ensure corporate accountability.
2026-06-10 14:09:46
Aquestive Therapeutics (AQST) shareholders strongly supported all proposals at their 2026 AGM. The meeting highlighted progress towards FDA approval and commercial launch of Anaphylm, global regulatory advancements, and ongoing pipeline development. No new material non-public information was disclosed during the Q&A session.
2026-06-04 18:40:06
Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (AQST) for potential corporate wrongdoing. The firm encourages investors who purchased AQST securities before June 16, 2025, and continue to hold them, to contact them to assist in the investigation. The representation is on a contingency fee basis, meaning no upfront cost to investors.
2026-06-02 21:09:50
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Aquestive Therapeutics, Inc. (AQST) stockholders who purchased securities prior to June 16, 2025. The investigation focuses on possible corporate wrongdoing by Aquestive and its officers/directors. The law firm encourages affected investors to contact them for more information, noting that they operate on a contingency fee basis.
